Skip to Content

Seebri Neohaler Approval History

FDA Approved: Yes (First approved October 29, 2015)
Brand name: Seebri Neohaler
Generic name: glycopyrrolate
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: COPD

Seebri Neohaler (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Seebri Neohaler

DateArticle
Oct 29, 2015Approval FDA Approves Seebri Neohaler (glycopyrrolate) for COPD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide